Glenmark Pharmaceuticals Limited has announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company’s Board of Directors approved these results, which include standalone and consolidated financial statements. Key figures such as profit before tax, profit after tax, and total comprehensive income for the periods are detailed in the accompanying statements.
Glenmark Pharmaceuticals Announces Financial Results for Q2 and H1 FY27
Mumbai, November 5, 2026 – Glenmark Pharmaceuticals Limited today announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company’s Board of Directors, at a meeting held on the same date, reviewed and approved these results, along with the limited review report thereon.
Standalone Financial Highlights
For the quarter ended September 30, 2026, Glenmark Pharmaceuticals reported a consolidated profit after tax of ₹4,348.94 million, compared to a loss of ₹7,391.89 million in the same period of the previous year. Total comprehensive income for the quarter stood at ₹4,197.07 million.
The standalone results for the half year ended September 30, 2026, showed a profit after tax of ₹11,705.31 million, a significant improvement from a loss of ₹4,089.63 million in the corresponding period of the previous year. The total comprehensive income for the half year was ₹11,559.50 million.
Consolidated Financial Highlights
On a consolidated basis, for the quarter ended September 30, 2026, the company reported a profit after tax of ₹2,638.30 million. For the half year ended September 30, 2026, the consolidated profit after tax was ₹7,466.58 million. The consolidated total comprehensive income for the quarter was ₹2,314.48 million, and for the half year it was ₹7,547.24 million.
The financial results reflect the company’s performance across its operations for the specified periods. Further details on revenue, expenses, and other comprehensive income are available in the detailed financial statements.
Source: BSE
